SEC inquiry
Executive Summary
Bristol "continues to believe that its accounting treatment of domestic wholesaler build-up has been completely appropriate," CEO Peter Dolan declares. The company specifically discussed its treatment of Medicaid accrual rates associated with the wholesaler inventory issues before recording a special charge for that amount in first quarter earnings, Dolan says (1"The Pink Sheet" April 29, p. 15)...
You may also be interested in...
Bristol Revises Product Overstocking Impact With $262 Mil. Medicaid Accrual
Bristol-Myers Squibb is increasing its estimate of the impact of wholesaler overstocking by $262 mil. to reflect an adjustment to the amount it has set aside for Medicaid rebate payments
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.